SYSTEMS AND METHODS FOR INTRA-TARGET MICRODOSING (ITM)

• US 20160074536A1
• Filed: 09/17/2014
• Published: 03/17/2016
• Est. Priority Date: 09/19/2013
• Status: Abandoned Application

• Current Assignee: Tal Burt
• Original Assignee: Tal Burt
• Inventors: Burt, Tal
• Application Number:
  US14/488,655
• Publication Number:
  US 20160074536A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61B 5/02007 Evaluating blood vessel condition, e.g. elasticity, compliance
• CPC Class Codes: A61B 5/02028 Determining haemodynamic parameters not otherwise provided for, e.g. cardiac contractility or left ventricular ejection fraction
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/14546 for measuring analytes not otherwise provided for, e.g. ions, cytochromes
• CPC Class Codes: A61B 5/201 Assessing renal or kidney functions
• CPC Class Codes: A61B 5/24 Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
• CPC Class Codes: A61B 5/4064 Evaluating the brain A61B5/031, A61B5/369, A61B5/14553 take precedence
• CPC Class Codes: A61B 5/4244 liver
• CPC Class Codes: A61B 5/425 pancreas
• CPC Class Codes: A61B 5/4848 Monitoring or testing the effects of treatment, e.g. of medication
• CPC Class Codes: A61B 6/037 Emission tomography
• CPC Class Codes: A61K 49/0004 Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
• CPC Class Codes: A61K 51/0491 Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
• CPC Class Codes: A61M 5/1723 using feedback of body parameters, e.g. blood-sugar, pressure measurement of body parameters A61B5/00
• CPC Class Codes: G01N 33/5088 of vertebrates

Abstract

Systems and methods for intra-target microdosing are disclosed. According to an aspect, a method for intra-target microdosing includes administering a microdose of drug into target tissue within a subject. The method also includes measuring efficacy of the administered drug to the target tissue.

Claims

1. A method for intra-target microdosing, the method comprising:

administering a microdose of drug into target tissue within a subject; and

measuring efficacy of the administered drug to the target tissue.

2. The method of claim 1, wherein the target tissue includes one of an artery and an organ.

3. The method of claim 1, wherein the target tissue includes one of peripheral vascular, periphery, liver, kidney, brain, pancreas, blood, and central nervous system.

4. The method of claim 1, wherein the subject is a human.

5. The method of claim 1, wherein the target tissue is a body area about 1/100^th of the total body mass of the subject.

6. The method of claim 1, wherein the microdose of drug is about 1/100^th or less of a total body minimal pharmacological dose for the subject.

7. The method of claim 1, wherein the microdose of drug is about 100 μ

g or less.

8. The method of claim 1, wherein the drug is one of nitrates, inotropes, analgesics, chemotherapy, anticoagulants, immune modulators, sodium glucose, cotransporter-2 (SGLT-2), inhibitors, central nervous system stimulants, and depressants.

9. The method of claim 1, wherein measuring the efficacy comprises measuring a biomarker.

10. The method of claim 9, wherein the biomarker is one of vasodilation, vasoconstriction, analgesia, receptor binding, coagulation parameters, platelet aggregation, cytokines, glucose absorption in proximal tubule, and neuronal activity.

11. A system for intra-target microdosing, the method comprising:

drug-administering equipment configured to administer a microdose of drug into target tissue within a subject; and

a sensor configured to measure efficacy of the administered drug to the target tissue.

12. The system of claim 11, wherein the target tissue includes one of an artery and an organ.

13. The system of claim 11, wherein the target tissue includes one of peripheral vascular, periphery, liver, kidney, brain, pancreas, blood, and central nervous system.

14. The system of claim 11, wherein the subject is a human.

15. The system of claim 11, wherein the target tissue is a body area about 1/100^th of the total body mass of the subject.

16. The system of claim 11, wherein the microdose of drug is about 1/100^th or less of a total body minimal pharmacological dose for the subject.

17. The system of claim 11, wherein the microdose of drug is about 100 μ

g or less.

18. The system of claim 11, wherein the drug is one of nitrates, inotropes, analgesics, chemotherapy, anticoagulants, immune modulators, sodium glucose, cotransporter-2 (SGLT-2), inhibitors, central nervous system stimulants, and depressants.

19. The system of claim 11, wherein the sensor is configured to measure a biomarker.

20. The system of claim 19, wherein the biomarker is one of vasodilation, vasoconstriction, analgesia, receptor binding, coagulation parameters, platelet aggregation, cytokines, glucose absorption in proximal tubule, and neuronal activity.